“Short-term efficacy of vedolizumab in patients with inflammatory bowel disease in real-life settings in Bosnia and Herzegovina” (2024) Biomolecules and Biomedicine, 24(5), pp. 1400–1406. doi:10.17305/bb.2024.10433.